エピソード

  • New ACC/AHA Dyslipidemia Guidelines Released

    New ACC/AHA Dyslipidemia Guidelines Released
    2026/03/18

    In this week's View, Dr. Eagle looks at data from the STS/ACC TVT Registry on off-label transcatheter valve interventions that demonstrate reduced residual tricuspid regurgitation (TR) and improved quality of life. He then explores the REVNOVATE-COMPLEX-PCI study that investigates the benefits of intravascular imaging guidance for five years. Finally, Dr. Eagle summarizes the ACC/AHA's newly released clinical guidelines for managing dyslipidemia.

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    8 分
  • Beta-Blocker vs. Calcium-Channel Blocker in HCM

    Beta-Blocker vs. Calcium-Channel Blocker in HCM
    2026/03/11
    In this week's View, Dr. Eagle looks at the differential effect of bisoprolol versus verapamil in nonobstructive hypertrophic cardiomyopathy (HCM) treatment. He then explores lower heart failure (HF) hospitalization risk in patients with type 2 diabetes, comparing GLP-1RAs to DPP-4 inhibitors and similar outcomes with SGLT-2 inhibitors. Dr. Eagle then examines the use of shared decision-making and decision aids in percutaneous left atrial appendage occlusion (LAAO). Finally, the iModern trial, which compares immediate percutaneous coronary intervention (PCI) guided by instantaneous wave-free ratio (iFR) and deferred PCI guided by cardiac stress magnetic resonance imaging (MRI) in patients with STEMI and multivessel disease, is discussed.  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    9 分
  • Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation

    Increased Mortality and TAVR; Wine Intake and CV Risk; PVI & Drug-Refractory Paroxysmal Atrial Fibrillation
    2026/03/04
    In this week's View, Dr. Eagle looks at increased one-year mortality in younger patients undergoing transcatheter aortic valve replacement (TAVR). He then explores the PREDIMED trial which found that adherence to the Mediterranean diet plus moderate wine intake was associated with reduced cardiovascular risk and mortality. Finally, Dr. Eagle examines 20-year outcomes for pulmonary vein isolation (PVI) in patients with drug-refractory paroxysmal atrial fibrillation (AFib).  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    7 分
  • Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism

    Self-Expanding TAVR vs Surgery; Ticagrelor vs Prasugrel in PCI; New Guidelines for Treatment of Acute Pulmonary Embolism
    2026/02/24
    In this week's View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults.  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    8 分
  • ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF

    ORBITA-2 & PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF
    2026/02/04
    In this week's View, Dr. Eagle looks at the ORBITA-2 trial and how percutaneous coronary intervention (PCI) may lead to greater symptom relief in older adults. He then explores the EQUAL trial that investigated how Apple smartwatch monitoring improves atrial fibrillation (AFib) detection. Finally, Dr. Eagle examines revelations from the EMPEROR-Preserved trial regarding interaction between SGLT2 inhibitors and baseline magnesium levels in treating patients who have either heart failure (HF) or HF with preserved ejection fraction (HFpEF).  Subscribe to Eagle's Eye View  
    続きを読む 一部表示
    8 分
  • Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes

    Exercise Testing & Systolic Blood Pressure; the Navitor TAVR valve; the ABILITY Diabetes Global Trial & Stent Comparisons for People with Diabetes
    2026/01/28

    In this week's View, Dr. Eagle looks at exercise systolic blood pressure (SBP) during stress testing related to cardiovascular (CV) events. He then explores the novel Navitor transcatheter heart valve (THV) and its safety and effectiveness in younger patients requiring transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle examines the value of 18F-FAPI PET/CT imaging and its role in assessing risk in patients with pulmonary arterial hypertension (PAH).

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    7 分
  • The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT

    The State of CV Health in the US; Semaglutide and Reduced Hospital Admissions; D-Dimer and Its Use in Ruling Out DVT
    2026/01/21

    In this week's View, Dr. Eagle comments on the recently published JACC Cardiovascular (CV) Statistics report which evaluates the management of CV risk factors in the United States. He then explores the use of semaglutide and its association with reduced hospital admissions and length of stay. Finally, Dr. Eagle examines the multicenter, multinational ADJUST-DVT study on the age-adjusted use of D-dimer cut-offs for patients with suspected deep vein thrombosis.   

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    7 分
  • Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes

    Reducing Fat & Reducing Mortality & Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes
    2026/01/14

    In this week's View, Dr. Eagle evaluates the impacts that reducing saturated fat have on mortality, nonfatal myocardial infarction (NFMI), and stroke in high-risk individuals. He then explores the SURPASS-CVOT study which considers if tirzepatide is superior to dulaglutide in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). Next, he summarizes the FINEARTS-HF study and its investigation of finerenone and hypotension and CV outcomes according to baseline kidney function.  Finally, Dr. Eagle examines how low operator volume is associated with worse transcatheter aortic valve replacement (TAVR) and mitral transcatheter edge-to-edge repair (MTEER) outcomes.   

     Subscribe to Eagle's Eye View  

    続きを読む 一部表示
    9 分